Related Experiment Video

Updated: Aug 29, 2026

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

[Mild cognitive disorder. Questions of definition, diagnosis, prognosis and therapy]

A Kurz1, J Diehl, M Riemenschneider

  • 1Klinik für Psychiatrie und Psychotherapie, Technische Universität München. alexander.kurz@lrz.tum.de

Der Nervenarzt
|January 15, 2004
PubMed

Insights

Mild cognitive impairment (MCI) affects 17% of those over 65, often showing Alzheimer's disease features. Early intervention in predementia Alzheimer's disease is crucial for potential treatment benefits.

Area of Science:

  • Neurology
  • Neuroscience
  • Geriatrics

Context:

  • Mild cognitive impairment (MCI) is a heterogeneous syndrome characterized by cognitive decline exceeding normal aging but not dementia severity.
  • Prevalence of MCI is estimated at 17% in individuals over 65 years old.
  • A significant proportion of MCI cases, especially the amnestic type, exhibit neuropathological features of Alzheimer's disease.

Purpose:

  • To explore the heterogeneous nature of mild cognitive impairment (MCI) and its relationship with Alzheimer's disease.
  • To highlight the diagnostic markers and progression rates of MCI towards dementia.
  • To discuss the potential for therapeutic interventions in early-stage Alzheimer's disease and predementia stages.

Summary:

  • MCI presents with significant cognitive deterioration, with 10-15% progressing annually to dementia, often linked to Alzheimer's disease.
  • Diagnostic tools like MRI, PET scans, and CSF biomarkers can reveal underlying neurodegenerative processes.
  • The potential benefits of current symptomatic treatments for MCI and predementia Alzheimer's disease remain under investigation.

Impact:

  • Understanding MCI's heterogeneity is key for accurate diagnosis and prognosis.
  • Identifying patients with predementia Alzheimer's disease is critical for developing and testing neuroprotective treatments.
  • Early-stage Alzheimer's disease patients represent a vital cohort for interventions aimed at slowing neurodegeneration.

More Related Videos

Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients07:42

Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients

Published on: December 16, 2022

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease06:23

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

Published on: October 13, 2016

Related Concept Videos

Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...